In comparison, among 1375 patients treated with crizotinib (any dose) for ALK-positive NSCLC in clinical trials, median age was 52 years, 56% were female, and 44% were Asian, of whom 30% were Korean. Here, ALK is linked to non-small cell lung carcinoma.